Profile data is unavailable for this security.
About the company
Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases, independently and with its strategic collaborators. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. Its diverse development pipeline consists of 45 therapeutic and vaccine programs, nine of which are in late-stage development. Its products include COVID-19 vaccines (mRNA-1273/Spikevax, next-generation mRNA-1283), RSV vaccine (mRNA-1345), Seasonal influenza vaccines (mRNA-1010, mRNA-1011, mRNA-1012, mRNA-1020 and mRNA-1030), Combination vaccines (mRNA-1083, mRNA-1230, mRNA-1045 and mRNA-1365), CMV vaccine (mRNA-1647), EBV vaccine (mRNA-1189 and mRNA-1195) and others.
- Revenue in USD (TTM)6.85bn
- Net income in USD-4.71bn
- Incorporated2016
- Employees5.60k
- LocationModerna Inc200 Technology SqCambridge 02139-3578United StatesUSA
- Phone+1 (617) 714-6500
- Fax+1 (617) 583-1998
- Websitehttps://www.modernatx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICON PLC | 8.12bn | 612.34m | 27.18bn | 41.10k | 44.52 | 2.94 | 22.68 | 3.35 | 7.40 | 7.40 | 98.17 | 112.02 | 0.4752 | -- | 2.99 | 197,571.20 | 3.59 | 3.93 | 4.28 | 4.80 | 29.66 | 28.91 | 7.55 | 7.37 | -- | 3.15 | 0.2901 | -- | 4.89 | 25.62 | 21.18 | 13.67 | 23.79 | -- |
Biogen Inc | 9.84bn | 1.16bn | 31.45bn | 7.57k | 27.11 | 2.12 | 18.99 | 3.20 | 7.98 | 7.98 | 67.67 | 102.14 | 0.3827 | 1.31 | 4.64 | 1,299,287.00 | 4.52 | 12.53 | 5.20 | 14.83 | 74.24 | 81.84 | 11.81 | 26.93 | 1.26 | 3.86 | 0.3192 | 0.00 | -3.32 | -6.07 | -61.89 | -23.58 | -18.87 | -- |
DuPont de Nemours Inc | 12.07bn | 494.00m | 31.95bn | 24.00k | 73.77 | 1.36 | 19.01 | 2.65 | 1.04 | 0.9256 | 26.77 | 56.45 | 0.302 | 3.50 | 4.94 | 502,833.30 | 1.33 | 0.3709 | 1.48 | 0.468 | 35.08 | 35.69 | 4.42 | 1.97 | 1.73 | 6.61 | 0.2398 | 414.03 | -7.29 | -11.79 | -51.19 | 11.24 | -30.66 | -20.59 |
Gartner Inc | 5.91bn | 882.47m | 37.49bn | 20.24k | 43.45 | 55.34 | 34.92 | 6.35 | 11.07 | 11.07 | 74.13 | 8.69 | 0.7805 | -- | 3.68 | 291,888.90 | 11.66 | 8.24 | 22.74 | 14.76 | 67.78 | 67.55 | 14.94 | 12.20 | -- | 12.01 | 0.7832 | -- | 7.87 | 8.24 | 9.24 | 49.78 | -4.06 | -- |
Moderna Inc | 6.85bn | -4.71bn | 42.34bn | 5.60k | -- | 3.05 | -- | 6.18 | -12.39 | -12.39 | 17.68 | 36.27 | 0.3093 | 8.15 | 6.01 | 1,222,857.00 | -21.29 | 20.95 | -25.94 | 29.51 | 31.47 | -- | -68.84 | 32.10 | 3.36 | -- | 0.0399 | 0.00 | -64.45 | 119.28 | -156.37 | -- | 46.22 | -- |
Iqvia Holdings Inc | 14.98bn | 1.36bn | 45.84bn | 87.00k | 34.61 | 7.50 | 18.46 | 3.06 | 7.30 | 7.30 | 80.42 | 33.67 | 0.5761 | -- | 4.76 | 172,229.90 | 5.22 | 3.24 | 6.80 | 4.07 | 34.96 | 34.32 | 9.06 | 6.03 | -- | 3.24 | 0.6911 | 0.00 | 3.98 | 7.55 | 24.47 | 43.39 | 7.17 | -- |
Holder | Shares | % Held |
---|---|---|
Baillie Gifford & Co.as of 31 Dec 2023 | 45.65m | 11.95% |
The Vanguard Group, Inc.as of 31 Dec 2023 | 32.51m | 8.51% |
BlackRock Fund Advisorsas of 31 Dec 2023 | 16.97m | 4.44% |
SSgA Funds Management, Inc.as of 31 Dec 2023 | 14.62m | 3.83% |
Th�l�me Partners LLPas of 31 Dec 2023 | 7.35m | 1.92% |
Wellington Management Co. LLPas of 31 Dec 2023 | 7.23m | 1.89% |
Geode Capital Management LLCas of 31 Dec 2023 | 6.55m | 1.71% |
Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 5.83m | 1.53% |
Capital Research & Management Co. (World Investors)as of 31 Dec 2023 | 3.63m | 0.95% |
Manulife Investment Management (US) LLCas of 31 Dec 2023 | 3.54m | 0.93% |